Skip to content

A retrospective case report series of patients (post-marketing) Receiving Olanzapine IntraMuscular Outside of Product Monograph doses and indications: assessing safety and tolerability

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN76803177
Enrollment
10
Registered
2006-08-31
Start date
2006-07-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various mental disorders under Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV) Mental and Behavioural Disorders Various mental disorders under Diagnostic and Statistical Manual of mental disorders fourth edition (DSM-IV)

Interventions

The intervention will be based on clinicians observations where the included patients have recieved Olanzapine IM.

Sponsors

London Health Sciences Centre (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients whom have received Olanzapine IM in doses exceeding doses stated in literature or for uses not listed in the current edition of the Compendium of Pharmaceuticals and Specialties.

Exclusion criteria

Exclusion criteria: Patients under 16 or over 70 years of age, or those whom have a documented allergy or sensitivity to olanzapine, also patients whom have used the olanzapine IM within normal dosing parameters.

Design outcomes

Primary

MeasureTime frame
Risk/benefit assessment of olanzapine IM being used in the included patients.

Secondary

MeasureTime frame
Demographics and concurrent medications resulting in therapeutic issues (post-marketing surveillance).

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026